MX2015011624A - Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras. - Google Patents
Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras.Info
- Publication number
- MX2015011624A MX2015011624A MX2015011624A MX2015011624A MX2015011624A MX 2015011624 A MX2015011624 A MX 2015011624A MX 2015011624 A MX2015011624 A MX 2015011624A MX 2015011624 A MX2015011624 A MX 2015011624A MX 2015011624 A MX2015011624 A MX 2015011624A
- Authority
- MX
- Mexico
- Prior art keywords
- active agent
- pharmaceutical compositions
- particle size
- agent nanoparticles
- spray dried
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 10
- 239000013543 active substance Substances 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000007921 spray Substances 0.000 abstract 4
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente composiciones farmacéuticas secas adecuadas para el suministro transmucosal, que comprende partículas secas, tales como partículas secadas por aspersión, que incluyen nanopartículas de agente farmacéuticamente activo, un aglutinante, y un portador farmacéuticamente aceptable, donde las nanopartículas de agente activo tienen un diámetro promedio de tamaño de partícula antes del procesamiento de menos que aproximadamente 1 µm, y donde hasta 10% de las partículas secadas por aspersión tienen un tamaño de partícula de menos que 10 µm; al menos 50% de las partículas secadas por aspersión tienen un tamaño de partícula de al menos aproximadamente 15 µm; y al menos 90% de las partículas secadas por aspersión tienen un tamaño de partícula de hasta aproximadamente 55 µm. También se proporcionan métodos para elaborar tales composiciones farmacéuticas y métodos terapéuticos que comprenden la administración transmucosamente de las composiciones, tal como intranasalmente o intravaginalmente, o por otras vías de administración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772095P | 2013-03-04 | 2013-03-04 | |
| PCT/US2014/019833 WO2014137877A1 (en) | 2013-03-04 | 2014-03-03 | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011624A true MX2015011624A (es) | 2015-12-17 |
| MX375187B MX375187B (es) | 2025-03-06 |
Family
ID=47901822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011624A MX375187B (es) | 2013-03-04 | 2014-03-03 | Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10695295B2 (es) |
| EP (1) | EP2964199B1 (es) |
| JP (1) | JP6564708B2 (es) |
| CN (1) | CN105307639B (es) |
| AU (1) | AU2014226192B2 (es) |
| BR (1) | BR112015021525B1 (es) |
| CA (1) | CA2901015A1 (es) |
| CY (1) | CY1124635T1 (es) |
| DK (1) | DK2964199T3 (es) |
| ES (1) | ES2804702T3 (es) |
| HR (1) | HRP20201103T1 (es) |
| HU (1) | HUE050050T2 (es) |
| IL (1) | IL240867B (es) |
| LT (1) | LT2964199T (es) |
| MX (1) | MX375187B (es) |
| PL (1) | PL2964199T3 (es) |
| PT (1) | PT2964199T (es) |
| RS (1) | RS60481B1 (es) |
| RU (1) | RU2715714C2 (es) |
| SI (1) | SI2964199T1 (es) |
| SM (1) | SMT202000349T1 (es) |
| WO (1) | WO2014137877A1 (es) |
| ZA (1) | ZA201505852B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2964199T (pt) | 2013-03-04 | 2020-05-12 | Besins Healthcare Lu Sarl | Composições farmacêuticas secas compreendendo nanoparticulas do agentes ativos, limitadas a partículas transportadoras |
| WO2018025089A2 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Pharmaceutical compositions |
| US20200179277A1 (en) * | 2017-05-19 | 2020-06-11 | Milton S. Jackson | Appetite suppressant |
| JP7453770B2 (ja) * | 2019-10-25 | 2024-03-21 | 松本油脂製薬株式会社 | 複合粒子及びその製造方法 |
| EP4358748A1 (en) * | 2021-06-25 | 2024-05-01 | Nicoventures Trading Limited | Oral products and method of manufacture |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| FR2575678B1 (fr) | 1985-01-04 | 1988-06-03 | Saint Gobain Vitrage | Ejecteur pneumatique de poudre |
| DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| KR100568436B1 (ko) * | 1996-02-27 | 2007-04-25 | 데이진 가부시키가이샤 | 분말상경비투여조성물 |
| AU5305899A (en) | 1998-08-26 | 2000-03-21 | Teijin Limited | Powdery pernasal compositions |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| PT1175214E (pt) | 1999-12-08 | 2005-04-29 | Pharmacia Corp | Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico |
| AU2002346143B2 (en) | 2001-07-05 | 2007-10-04 | Translational Research Ltd | Compositions for nasal administration of insulin |
| CN1176649C (zh) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| PL211224B1 (pl) * | 2003-01-31 | 2012-04-30 | Orexo Ab | Kompozycja farmaceutyczna do leczenia ostrych zaburzeń przez podjęzykowe lub donosowe podawanie oraz jej zastosowanie |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| US8673360B2 (en) | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
| US7947308B2 (en) * | 2005-07-20 | 2011-05-24 | Raimar Loebenberg | Effervescent powders for inhalation |
| EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| CA2647073A1 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Drug microparticles |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| ES2652415T3 (es) | 2006-12-26 | 2018-02-02 | Shin Nippon Biomedical Laboratories, Ltd. | Preparación para aplicación transnasal |
| GB0716907D0 (en) | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
| WO2010033832A2 (en) * | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| WO2010131486A1 (en) * | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| SMT202000077T1 (it) * | 2009-05-29 | 2020-03-13 | Pearl Therapeutics Inc | Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati |
| US20110262502A1 (en) | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| NZ603044A (en) * | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| JP2014504260A (ja) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
| EP2540281A1 (en) * | 2011-06-30 | 2013-01-02 | LEK Pharmaceuticals d.d. | Solid self-microemulsifying systems |
| PT2964199T (pt) | 2013-03-04 | 2020-05-12 | Besins Healthcare Lu Sarl | Composições farmacêuticas secas compreendendo nanoparticulas do agentes ativos, limitadas a partículas transportadoras |
-
2014
- 2014-03-03 PT PT147107577T patent/PT2964199T/pt unknown
- 2014-03-03 SM SM20200349T patent/SMT202000349T1/it unknown
- 2014-03-03 SI SI201431571T patent/SI2964199T1/sl unknown
- 2014-03-03 WO PCT/US2014/019833 patent/WO2014137877A1/en not_active Ceased
- 2014-03-03 HR HRP20201103TT patent/HRP20201103T1/hr unknown
- 2014-03-03 RU RU2015141792A patent/RU2715714C2/ru active
- 2014-03-03 MX MX2015011624A patent/MX375187B/es active IP Right Grant
- 2014-03-03 AU AU2014226192A patent/AU2014226192B2/en active Active
- 2014-03-03 BR BR112015021525-4A patent/BR112015021525B1/pt active IP Right Grant
- 2014-03-03 RS RS20200797A patent/RS60481B1/sr unknown
- 2014-03-03 DK DK14710757.7T patent/DK2964199T3/da active
- 2014-03-03 LT LTEP14710757.7T patent/LT2964199T/lt unknown
- 2014-03-03 EP EP14710757.7A patent/EP2964199B1/en active Active
- 2014-03-03 CN CN201480011817.7A patent/CN105307639B/zh active Active
- 2014-03-03 US US14/195,023 patent/US10695295B2/en active Active
- 2014-03-03 JP JP2015561494A patent/JP6564708B2/ja active Active
- 2014-03-03 PL PL14710757T patent/PL2964199T3/pl unknown
- 2014-03-03 ES ES14710757T patent/ES2804702T3/es active Active
- 2014-03-03 CA CA2901015A patent/CA2901015A1/en not_active Abandoned
- 2014-03-03 HU HUE14710757A patent/HUE050050T2/hu unknown
-
2015
- 2015-08-14 ZA ZA2015/05852A patent/ZA201505852B/en unknown
- 2015-08-26 IL IL240867A patent/IL240867B/en active IP Right Grant
-
2020
- 2020-06-25 US US16/911,598 patent/US10918601B2/en active Active
- 2020-06-25 CY CY20201100589T patent/CY1124635T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502516B1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
| MX2012003204A (es) | Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado. | |
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| NZ726746A (en) | Stable cannabinoid formulations | |
| TN2015000395A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| CU24504B1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol y un proceso que incluye un paso de granulación para preparar el mismo | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| IN2013MU03583A (es) | ||
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| DOP2014000269A (es) | Nueva dosificación y formulación | |
| CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| CL2015002702A1 (es) | Composiciones farmacéuticas micronizadas. | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| BR112015014180A2 (pt) | composições de gel | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
| MX2015016678A (es) | Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico. | |
| IN2013MU03567A (es) | ||
| PH22011000489U3 (en) | Solid pharmaceutical herbal compositions | |
| AR098867A1 (es) | Composición farmacéutica en polvo seco para inhalación | |
| MX383685B (es) | Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. | |
| NI201400138A (es) | Nueva dosificación y formulación. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |